Results 31 to 40 of about 9,825 (155)

Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and their combined dosage form

Future Journal of Pharmaceutical Sciences, 2018
Objective: A simple, specific, accurate and economic reverse phase liquid chromatographic method was developed for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and tablet dosage form.
S.K. Mastanamma, S.K. Chandini, S.K. Reehana, P. Saidulu   +3 more
doaj   +1 more source

Novel combined single dose anti-hepatitis C therapy: a pilot study

Scientific Reports, 2021
The new anti-hepatitis C virus (HCV) molecules improve treatment regimens and outcomes, but there are drawbacks. New combinations should target the HCV infectious cycle and be effective against all HCV genotypes.
Gamal Shiha, Reham Soliman, Mohamed Elbasiony, Noureldien H. E. Darwish, Shaker A. Mousa   +4 more
doaj   +1 more source

The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes

Scientific Reports
Sofosbuvir is one of the crucial drugs used in the treatment of chronic hepatitis C virus (HCV) in adults and children with compensated liver disease, including cirrhosis. It may be used alone or with other drugs.
Rana A. Ali, Eatemad A. Awadalla, Yahia A. Amin, Samer S. Fouad, Maha Abd-El Baki Ahmed, Mohammed H. Hassan, Emaad Abdel-Kahaar, Rehab H. Abdel-Aziz   +7 more
doaj   +1 more source

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

Journal of Virus Eradication, 2016
Objectives: Novel treatments for hepatitis C demonstrate high cure rates, but current high prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly lower drug prices.
Andrew Hill, Bryony Simmons, Dzintars Gotham, Joseph Fortunak   +3 more
doaj   +1 more source

Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa

BMC Health Services Research, 2022
Background Although direct-acting antivirals (DAA) have become standard care for patients with chronic hepatitis C worldwide, there is no evidence for their value for money in sub-Saharan Africa.
Sylvie Boyer, Maël Baudoin, Marie Libérée Nishimwe, Melina Santos, Maud Lemoine, Gwenaëlle Maradan, Babacar Sylla, Charles Kouanfack, Patrizia Carrieri, Abbas Mourad, Nicolas Rouveau, Raoul Moh, Moussa Seydi, Alain Attia, Maame Esi Woode, Karine Lacombe   +15 more
doaj   +1 more source

Long‐Term Neurologic Exam Findings in People Diagnosed and Treated During Acute HIV Infection

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Evaluate clinical and laboratory correlates of abnormal neurologic exam findings after acute HIV infection (AHI). Methods Participants from the RV254/SEARCH 010 cohort in Bangkok underwent standardized neurologic examinations at Weeks 0 (AHI), 12, 96, and 288 following antiretroviral therapy (ART).
Kathryn B. Holroyd, Tyler Hamby, Carlo Sacdalan, Somchai Sriplienchan, Pathariya Promensa, Luxenaree Poonpitak, Netsiri Dumrongpisutikul, Eugène Kroon, Sandhya Vasan, Robert Paul, Ferron O'Campo, Lydie Trautmann, Phillip Chan, Serena Spudich, on behalf of the RV254/SEARCH 010 Study Team, Julie Ake, Sandhya Vasan, Lydie Trautmann, Merlin Robb, Trevor Crowell, Donn Colby, Diane Bolton, Shelly Krebs, Leigh Ann Eller, Morgane Rolland, Rasmi Thomas, Dominic Paquin Proulx, Suteeraporn Pinyakorn, Tyler Hamby, Mark de Souza, Ellen Turk, Amber Moodley, Gerald Quarles, Jintanat Ananworanich, Denise Hsu, Victoria Polonis, Nelson Michael, Sheila Peel, COL Eric Garges, Alexandra Schuetz, Siriwat Akapirat, Bessara Nantapinit, Pornsuk Visudhiphan, Saowanit Getchalarat, Nampueng Churikanont, Sangsulee Thamakaison, Somchai Sriplienchan, Carlo Sacdalan, Pathariya Promsena, Luxe‐naree Poonpitak, Eugene Kroon, Nitiya Chomchey, Jintana Intasan, Varaporn Pothipala, Ferron Ocampo, Nittaya Phanuphak, Nipat Teeratakulpisan, Yuwaree Pichitchok, Anchalee Avihingsanon, Opass Putcharoen, Kiat Ruxrungtham, Thanyawee Puthanakit, Sopark Manasnayakorn, Phandee Watanaboonyongcharoen, Rungsun Rerknimitr, Irini Sereti, Daniel Douek, Eli Bortiz, Frank Maldarelli, Mary Kearney, Serena Spudich, Phillip Chan, Lishomwa Ndhlovu, Guinevere Li, Michael Corley, Victor Valcour, Peter Hunt, Jacob Estes, Afam Okoye, Jeff Lifson, Claire Deleage, Nicolas Chomont, Andres Finzi, Lyle McKinnon, Henrik Zetterberg, Robert Siliciano, Robert Paul, Julie Mannarino, Jonathan Li, John Mellors, Josh Cytkor, Dan Barouch, Michael Seaman, Boris Juelg, Alex Shalek, Timothy Schacker, Ashley Haase, Mario Stevenson, Wenjun Li, Arthur Kim, Sharon Lewin, Adam Carrico, Susana Valente, Fred Hutchinson, Josh Schiffer, Guido Ferrari, Beau Ances, Alberto Bosque, Katharine Bar, Killian Pohl, David Ho, Yaoxing Huang, Michael Busch, Mohamed Abdel‐Mohsen, Johanna Gostner, Brian Agan, Fatah Kashanchi, Greg Laird, Kathryn Holroyd   +118 more
wiley   +1 more source

Development and validation of RP HPLC method for the estimation of Sofosbuvir and related impurity in bulk and pharmaceutical dosage form

Future Journal of Pharmaceutical Sciences, 2021
Background The present work is aimed at development and validation of RP HPLC method which is simple, specific, precise, and accurate for estimation of Sofosbuvir and its process-related impurity in bulk and pharmaceutical dosage forms.
Shiny Ganji, Satyavati Dhulipala, Appala Raju Nemala   +2 more
doaj   +1 more source

Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. [PDF]

PLoS Neglected Tropical Diseases, 2019
Yellow fever virus (YFV) is a member of the Flaviviridae family. In Brazil, yellow fever (YF) cases have increased dramatically in sylvatic areas neighboring urban zones in the last few years. Because of the high lethality rates associated with infection
Caroline S de Freitas, Luiza M Higa, Carolina Q Sacramento, André C Ferreira, Patrícia A Reis, Rodrigo Delvecchio, Fabio L Monteiro, Giselle Barbosa-Lima, Harrison James Westgarth, Yasmine Rangel Vieira, Mayara Mattos, Natasha Rocha, Lucas Villas Bôas Hoelz, Rennan Papaleo Paes Leme, Mônica M Bastos, Gisele Olinto L Rodrigues, Carla Elizabeth M Lopes, Celso Martins Queiroz-Junior, Cristiano X Lima, Vivian V Costa, Mauro M Teixeira, Fernando A Bozza, Patrícia T Bozza, Nubia Boechat, Amilcar Tanuri, Thiago Moreno L Souza   +25 more
doaj   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection

Clinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) and ruzasvir (RZR) are pan‐genotypic HCV polymerase (NS5B) and NS5A inhibitors, respectively. In a single‐arm study (NCT05904470), 215 treatment‐naïve, adherent participants with chronic HCV (with or without cirrhosis) received BEM 550 mg QD plus RZR 180 mg QD for 8 weeks.
Carolin Zitzmann, Ruy M. Ribeiro, Aurelien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +1 more source